Endoscopic injection sclerotherapy in the management of 2105 patients with esophageal varices

Morimasa Tomikawa, Makoto Hashizume, Keishi Okita, Seigo Kitano, Masayuki Ohta, Hidefumi Higashi, Tomohiko Akahoshi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background. The objective of this study is to examine the overall clinical results of endoscopic injection sclerotherapy (EIS) for patients with esophageal varices in our institution. Methods. From January 1982 to May 2001, 2105 patients with esophageal varices were treated with EIS, which included prophylactic injections for patients with risky varices according to our criteria. Follow-up endoscopy was performed every 3 months, and recurrent varices were treated with additional EIS. Results. Acute variceal bleeding was controlled in 468 of 473 patients (98.9%). Esophageal varices were completely eradicated in 1757 of 2105 patients (83.5%) with 3.8 ± 1.6 sessions of EIS. The cumulative recurrence rates were 32.2% at 5 years, 36.5% at 10 years, and 37.8% at 15 years. The cumulative nonbleeding rates were 92.3% at 5 years, 90.1% at 10 years, and 89.5% at 15 years. The survival rate of acute bleeders was significantly lower than for both elective and prophylactic cases (P < . 05). The overall cumulative survival rate was 28.2% at 10 years. Conclusions. EIS is the first choice of treatment for esophageal variceal bleeding, and rebleeding was shown to be well controlled in a long-term follow-up with endoscopy and additional EIS. The lower survival rate observed in acute bleeders may therefore justify the use of prophylactic EIS.

Original languageEnglish
Pages (from-to)S171-S175
JournalSurgery
Volume131
Issue number1
DOIs
Publication statusPublished - Jan 1 2002

Fingerprint

Sclerotherapy
Esophageal and Gastric Varices
Injections
Survival Rate
Varicose Veins
Endoscopy
Hemorrhage
Recurrence

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Tomikawa, M., Hashizume, M., Okita, K., Kitano, S., Ohta, M., Higashi, H., & Akahoshi, T. (2002). Endoscopic injection sclerotherapy in the management of 2105 patients with esophageal varices. Surgery, 131(1), S171-S175. https://doi.org/10.1067/msy.2002.119500

Endoscopic injection sclerotherapy in the management of 2105 patients with esophageal varices. / Tomikawa, Morimasa; Hashizume, Makoto; Okita, Keishi; Kitano, Seigo; Ohta, Masayuki; Higashi, Hidefumi; Akahoshi, Tomohiko.

In: Surgery, Vol. 131, No. 1, 01.01.2002, p. S171-S175.

Research output: Contribution to journalArticle

Tomikawa, M, Hashizume, M, Okita, K, Kitano, S, Ohta, M, Higashi, H & Akahoshi, T 2002, 'Endoscopic injection sclerotherapy in the management of 2105 patients with esophageal varices', Surgery, vol. 131, no. 1, pp. S171-S175. https://doi.org/10.1067/msy.2002.119500
Tomikawa M, Hashizume M, Okita K, Kitano S, Ohta M, Higashi H et al. Endoscopic injection sclerotherapy in the management of 2105 patients with esophageal varices. Surgery. 2002 Jan 1;131(1):S171-S175. https://doi.org/10.1067/msy.2002.119500
Tomikawa, Morimasa ; Hashizume, Makoto ; Okita, Keishi ; Kitano, Seigo ; Ohta, Masayuki ; Higashi, Hidefumi ; Akahoshi, Tomohiko. / Endoscopic injection sclerotherapy in the management of 2105 patients with esophageal varices. In: Surgery. 2002 ; Vol. 131, No. 1. pp. S171-S175.
@article{f41cccad7df74b43b79703892dc4b4a6,
title = "Endoscopic injection sclerotherapy in the management of 2105 patients with esophageal varices",
abstract = "Background. The objective of this study is to examine the overall clinical results of endoscopic injection sclerotherapy (EIS) for patients with esophageal varices in our institution. Methods. From January 1982 to May 2001, 2105 patients with esophageal varices were treated with EIS, which included prophylactic injections for patients with risky varices according to our criteria. Follow-up endoscopy was performed every 3 months, and recurrent varices were treated with additional EIS. Results. Acute variceal bleeding was controlled in 468 of 473 patients (98.9{\%}). Esophageal varices were completely eradicated in 1757 of 2105 patients (83.5{\%}) with 3.8 ± 1.6 sessions of EIS. The cumulative recurrence rates were 32.2{\%} at 5 years, 36.5{\%} at 10 years, and 37.8{\%} at 15 years. The cumulative nonbleeding rates were 92.3{\%} at 5 years, 90.1{\%} at 10 years, and 89.5{\%} at 15 years. The survival rate of acute bleeders was significantly lower than for both elective and prophylactic cases (P < . 05). The overall cumulative survival rate was 28.2{\%} at 10 years. Conclusions. EIS is the first choice of treatment for esophageal variceal bleeding, and rebleeding was shown to be well controlled in a long-term follow-up with endoscopy and additional EIS. The lower survival rate observed in acute bleeders may therefore justify the use of prophylactic EIS.",
author = "Morimasa Tomikawa and Makoto Hashizume and Keishi Okita and Seigo Kitano and Masayuki Ohta and Hidefumi Higashi and Tomohiko Akahoshi",
year = "2002",
month = "1",
day = "1",
doi = "10.1067/msy.2002.119500",
language = "English",
volume = "131",
pages = "S171--S175",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Endoscopic injection sclerotherapy in the management of 2105 patients with esophageal varices

AU - Tomikawa, Morimasa

AU - Hashizume, Makoto

AU - Okita, Keishi

AU - Kitano, Seigo

AU - Ohta, Masayuki

AU - Higashi, Hidefumi

AU - Akahoshi, Tomohiko

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Background. The objective of this study is to examine the overall clinical results of endoscopic injection sclerotherapy (EIS) for patients with esophageal varices in our institution. Methods. From January 1982 to May 2001, 2105 patients with esophageal varices were treated with EIS, which included prophylactic injections for patients with risky varices according to our criteria. Follow-up endoscopy was performed every 3 months, and recurrent varices were treated with additional EIS. Results. Acute variceal bleeding was controlled in 468 of 473 patients (98.9%). Esophageal varices were completely eradicated in 1757 of 2105 patients (83.5%) with 3.8 ± 1.6 sessions of EIS. The cumulative recurrence rates were 32.2% at 5 years, 36.5% at 10 years, and 37.8% at 15 years. The cumulative nonbleeding rates were 92.3% at 5 years, 90.1% at 10 years, and 89.5% at 15 years. The survival rate of acute bleeders was significantly lower than for both elective and prophylactic cases (P < . 05). The overall cumulative survival rate was 28.2% at 10 years. Conclusions. EIS is the first choice of treatment for esophageal variceal bleeding, and rebleeding was shown to be well controlled in a long-term follow-up with endoscopy and additional EIS. The lower survival rate observed in acute bleeders may therefore justify the use of prophylactic EIS.

AB - Background. The objective of this study is to examine the overall clinical results of endoscopic injection sclerotherapy (EIS) for patients with esophageal varices in our institution. Methods. From January 1982 to May 2001, 2105 patients with esophageal varices were treated with EIS, which included prophylactic injections for patients with risky varices according to our criteria. Follow-up endoscopy was performed every 3 months, and recurrent varices were treated with additional EIS. Results. Acute variceal bleeding was controlled in 468 of 473 patients (98.9%). Esophageal varices were completely eradicated in 1757 of 2105 patients (83.5%) with 3.8 ± 1.6 sessions of EIS. The cumulative recurrence rates were 32.2% at 5 years, 36.5% at 10 years, and 37.8% at 15 years. The cumulative nonbleeding rates were 92.3% at 5 years, 90.1% at 10 years, and 89.5% at 15 years. The survival rate of acute bleeders was significantly lower than for both elective and prophylactic cases (P < . 05). The overall cumulative survival rate was 28.2% at 10 years. Conclusions. EIS is the first choice of treatment for esophageal variceal bleeding, and rebleeding was shown to be well controlled in a long-term follow-up with endoscopy and additional EIS. The lower survival rate observed in acute bleeders may therefore justify the use of prophylactic EIS.

UR - http://www.scopus.com/inward/record.url?scp=0036165404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036165404&partnerID=8YFLogxK

U2 - 10.1067/msy.2002.119500

DO - 10.1067/msy.2002.119500

M3 - Article

C2 - 11821806

AN - SCOPUS:0036165404

VL - 131

SP - S171-S175

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 1

ER -